Holen Sie sich die Stockscreener-App
20.00
14.60%
-3.42
Handel nachbörslich:
19.88
-0.12
-0.60%
Schlusskurs vom Vortag:
$23.42
Offen:
$23.25
24-Stunden-Volumen:
2.70M
Relative Volume:
5.29
Marktkapitalisierung:
$1.18B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-10.58
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-6.54%
1M Leistung:
+1.99%
6M Leistung:
-2.49%
1J Leistung:
-27.61%
1-Tages-Spanne:
$18.33
$23.31
1-Wochen-Bereich:
$18.33
$24.64
52-Wochen-Spanne:
$13.30
$29.79
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
20.00 | 1.39B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven Therapeutics Inc. stock daily chart insightsMarket Risk Analysis & Reliable Price Action Trade Plans - newser.com
Enliven Therapeutics showcases promising results for ELVN-001 in CML trial - Traders Union
Enliven (NASDAQ: ELVN) presents ELVN-001 CML data at ASH 2025 with >1 log transcript declines - Stock Titan
Is Enliven Therapeutics Inc. stock positioned well for digital economyJuly 2025 PreEarnings & Fast Entry High Yield Tips - newser.com
Can Enliven Therapeutics Inc. stock deliver strong Q4 earnings2025 Market Overview & Long-Term Growth Stock Strategies - newser.com
Is Enliven Therapeutics Inc. stock a contrarian buy2025 Short Interest & Fast Moving Trade Plans - newser.com
Using data filters to optimize entry into Enliven Therapeutics Inc.Oil Prices & Community Supported Trade Ideas - newser.com
Applying sector rotation models to Enliven Therapeutics Inc.Weekly Profit Summary & Daily Risk Controlled Trade Plans - newser.com
Why Enliven Therapeutics Inc. stock appeals to dividend seekers2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Enliven Therapeutics Inc. recovery potential after sell offExit Point & Risk Controlled Swing Alerts - newser.com
Is Enliven Therapeutics Inc. stock a safe haven assetWeekly Earnings Recap & Fast Entry Momentum Alerts - newser.com
Is Enliven Therapeutics Inc. stock cheap compared to fundamentalsInsider Selling & Free Expert Verified Stock Movement Alerts - newser.com
Automated trading signals detected on Enliven Therapeutics Inc.Portfolio Value Report & Safe Swing Trade Setups - newser.com
Real time breakdown of Enliven Therapeutics Inc. stock performanceWeekly Trade Review & Entry Point Confirmation Signals - newser.com
Is Enliven Therapeutics Inc a good long term investmentFederal Reserve Announcements & Build Wealth With Zero-Cost Tools - earlytimes.in
Enliven Therapeutics (ELVN): Evaluating Valuation Following Phase 1 ELVN-001 Update for Resistant Leukemia - Sahm
Will Enliven Therapeutics Inc. stock outperform tech sector in 2025Quarterly Portfolio Summary & Verified Technical Trade Signals - fcp.pa.gov.br
Will Enliven Therapeutics Inc. stock rally after Fed decisionsMarket Risk Summary & Real-Time Volume Surge Alerts - fcp.pa.gov.br
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):